AUTHOR INDEX
Volume 31
January-June 1985

Aarons, D., 177
Aedo, A.-R., 453
Agency for International Development, 11
Ali, H.M., 173
Alvarez, F., 261
Angulo, A.G., 509
Antar, S., 595
Back, D.J., 611
Bain, J., 65
Banerjee, R., 101
Baumgarten, S., 295
Bergquist, C., 111, 119
Bialy, G., 141
Blye, R.P., 141
Brache, V., 261
Brandeis, A., 643
Buret, J., 395
Cardenas, S., 361
Carrano-López, A., 43
Cekan, S.Z., 431
Chan, W.Y., 83
Chatterjee, A., 173
Chatterjee, R., 173
Cooke, I.D., 611
Cortés-Gallegos, V., 43
Cravioto, M.C., 361
Croxatto, H.B., 321, 643
Darod, M.F., 173
deChavez, I.R., 509
Dennemark, N., 207
Deslypere, J.P., 633
Diamond, M.P., 623
Díaz, S., 321, 643
Diaz-Sanchez, V., 361
Diczfalusy, E., 1, 431, 453
Donaldson, A., 159, 165
Donde, U.M., 71
Dong, L., 217
Doody, K., 65
Dorflinger, L.J., 557
Einen, M.A., 571
Estrada, A.V., 499, 509, 533, 543
Farraq, O.A., 595
Faúndes, A., 261
Feng, D., 217
Fotherby, K., 367
Frick, J., 151
Friedl, K.E., 409
Gahn, G., 583
Gallegos, A.J., 487, 499, 509, 523, 533, 543
Garza-Flores, J., 361
Gaspard, U.J., 395
Gawad. A.A., 595
Gibson, M.J., 91
Gillain, D., 395
Gödicke, H.-D., 207
Greene, J.W., 623
Gudmundsson, J., 119
Guzman, A., 499, 523, 543
Hammerstein, J., 295
Hanna, B.A., 185
Haspels, A.A., 275, 603
Holma, P., 231
Honore, L.H., 253
Hurst, P.R., 445
Jeffcoate, S.J., 159, 165
Jia, M., 217, 431
Johannisson, E., 453
Johansson, E., 261
Johansson, E.D.B., 195, 655
Joshi, J.V., 71
Joshi, U.M., 71
Kainz, P., 151
Kalla, N., 151
Kamel, M., 571
Ketting, E., 603
Kierkegaard, A., 29
Kock, N.G., 195
Kohtz, D.S., 91
Kral, J.G., 195
Kuhl, H., 583
Kurunmäki, H., 305
Lähteenmäki, P., 305
Lambotte, R., 395
Landgren, B.-M., 431, 453
Liew, D.F.M., 51
Lim, L.S., 471
Lin, S., 217
Lindberg, M.C., 141
Lithell, H., 123, 131
Lohiya, N.K., 421
Luukkainen, T., 305
März, W., 583
Matlin, S.A., 141, 159
McCarthy, T.G., 471

Moltz, L., 295
Naqvi, R.H., 141
National Institutes of Health, 11
Navarrete-Arellano, M., 43
Ng, C.S.A., 51
NIH/AID/PARFR Workshop on Research and Development of Immunological Methods of Fertility Regulation, 11
Nillius, S.J., 111, 119
Nilsson, L.O., 195
Nussbaumer, V., 151
Odlind, V., 123
Pakrashi, A., 101
Paulsen, C.A., 409
Pavez, M., 321, 643
Pedrón, N., 499, 509, 523, 533, 543
Peplow, P.V., 445
Perez-Palacios, G., 361
Perusquía, M., 543
Plymate, S.R., 409
Poirer, G.R., 177
Ponce-Monter, H., 499, 523, 533, 543
Population Council Committee for Contraception Research, 351
Program for the Applied Research on Fertility Regulation, 11, 243
Querido, L., 603
Rath, W., 207
Ratnam, S.S., 51, 471
Richardson, R., 177
Robinson, R., 177
Rodríguez, V., 361
Romberg, G., 583
Römmler, A., 295
Romus, M.A., 395
Saleh, F., 571
Sallam, H., 571
Sánchez, E., 543
Sankoli, G.M., 71
Sanyal, S., 101
Saxena, B.N., 71
Schane, H.P., 479
Schwartz, U., 295
Selinus, I., 123, 131
Sen, N.R., 101
Sharma, O.P., 421
Sharma, R.C., 421
Shroff, N.E., 611
Snyder, B.W., 479
So, K.C., 83
Sojo-Aranda, I., 43
Souka, A.R., 571
Sufi, S.B., 159, 165
Tam, P.P.L., 83
Taubert, H.-D., 583
Thiery, M., 331, 633
Thompson, J.M., 623
Tierno, P.M., Jr., 185
Toivonen, J., 305
Valencia, A., 499, 523, 533 543
VanHooydonk, J.E., 623
Van Der Pas, H., 331
Van Kets, H., 331
Van Santen, M.R., 275
Vermeulen, A., 633
Vessby, B., 123, 131
Victor, A., 131, 195
Virkar, K.D., 71
Wens, A., 523
Wentz, A.C., 623
Wide, L., 111
Wu, E., 217
Xiao, B., 217
Yan, W., 217
Yeung, H.W., 83
Yong, Y.M., 51, 471
Zhang, X., 217
Zhou, R., 141, 159

SUBJECT INDEX

VOLUME 31

JANUARY - JUNE 1985

Abortifacient efficacy, chloroquine (rat), 173
Abortion, immediate IUD insertion, 603
Abortion rate, use of sulprostone gel, 207
Abortions/1000 live births, legal and illegal, 1
Absorption of levonorgestrel, women with ulcerative colitis, conventional ileostomy and continent ileostomy reservoir, 195
Acceptability, contraceptive vaccines, 11
Acetylcholine, effect on uterine strips (rat), 543
Acid phosphatase level, effect of danazol + testosterone enanthate (monkey), 421
ACTH (adrenocorticotropic hormone)
ACTH concentration, effect of GnRH agonist (rat), 91
Albumin level, effect of ethinyl oestradiol + norethisterone acetate, 571
Amino acids incorporation, effect of gossypol (rat), 151
ε -Amino-n-caproic acid, effectiveness as competitor with seminal inhibitor for binding to epididymal sperm (mouse), 177
Amplification of toxic shock syndrome toxin-1 by intravaginal devices, 185
Anti-hormone vaccines, 11
Anticonvulsants and oral contraceptives, interaction in epileptic adolescents, 623
Apolipoproteins levels,
  effect of estradiol + norethindrone, 131
  effect of ethinylestradiol + desogestrel, 395
  effect of ethinylestradiol + levonorgestrel, 395
  effect of long-term hormonal contraception, 633
  effect of oral contraceptives, 367
  effect of ST-1435, 123
Atropine, effect on uterine strips (rat), 543
Basal release of testosterone,
  effect of gossypol on Leydig cells (mouse), 165
  effect of (+) and (-) gossypol on Leydig cells (mouse), 159
Biochemical composition of semen, effect of danazol + testosterone enanthate (monkey), 421
Biosynthetic activity, effect of β-momorcharin on endometrial cells (mouse), 83
Bleeding, immediate post-abortion IUD insertion, 603
Bleeding pattern,
  effect of estradiol + norethindrone, 131
  effect of estradiol cypionate + medroxyprogesterone acetate, 453
  effect of estradiol valerate + norethisterone enanthate, 453
  effect of ethinyl estradiol + desogestrel, 583
  effect of ethinyl estradiol + levonorgestrel, 583
  effect of GnRH agonist, 119
  effect of levonorgestrel, 351
  effect of LRH agonist, 111

effect of norethisterone or levonorgestrel pellet fused with cholesterol, 71
effect of ST-1435, 305
interaction of anticonvulsants and oral contraceptives, 623
Bleeding rate, use of sulprostone gel, 207
Blood, level of ethynylestradiol, 43
Blood pressure,
effect of levonorgestrel, 71
effect of norethisterone, 71
effect of ST-1435, 305
Body weight,
effect of GnRH agonist (rat), 91
effect of gossypol (hamster), 141
effect of levonorgestrel, 71
effect of norethisterone, 71
effect of ST-1435, 123, 305
Breast milk, norethisterone concentration during ethynodiol diacetate administration, 611
Carbohydrate metabolism,
effect of depo-medroxyprogesterone acetate, 51
effect of ST-1435, 123
Cardiovascular disease, effect of oral contraceptives and changes in lipid metabolilsm, 367
Cardiovascular disease and lipids, 367
Cardiovascular disease and oral contraceptives, 367
Cervical function, effect of Norplant® contraceptive implants, 261
Cervical mucus,
effect of levonorgestrel, 71
effect of norethisterone, 71
Cervical mucus quality, effect of levonorgestrel, 261
Cervical priming, use of sulprostone gel, 207
Cervix, incidence of group B-beta haemolytic streptococcal colonization, 595
Chinese women, endocrinological profile of normal menstrual cycle, 217
Chloroquine, premature evacuation of uterine conceptus (rat), 173
Cholesterol fused with norethisterone or levonorgestrel, clinical trial, 71
Cholesterol level,
effect of depo-medroxyprogesterone acetate, 51
effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
effect of estradiol + norethindrone, 131
effect of ethinylestradiol + desogestrel, 395
effect of ethinylestadiol + levonorgestrel, 395
effect of ethinyl oestradiol + norethisterone acetate, 571
effect of long-term hormonal contraception, 633
effect of oral contraceptives, 367
effect of ST-1435, 123
Cimetidine, effect on uterine strips (rat, guinea pig), 533
Citric acid level, effect of danazol + testosterone enanthate (monkey), 421
Clinical chemistry tests,
effect of copper T 200, 321
effect of levonorgestrel covered rods, 321

Clinical observations,
effect of ethinyl estradiol + desogestrel, 583
effect of ethinyl estradiol + levonorgestrel, 583
Colonization rate, group B-beta haemolytic streptococci in IUD users, 595
Complications, intrauterine applications of methyl cyanoacrylate for permanent sterilization, 243
Continent ileostomy reservoir, effect on absorption of levonorgestrel when administered into reservoir, 195
Contraception,
female methods available by year 2000, 1
male methods available by year 2000, 1
Contraceptive futurology, 1
Contraceptive sponge, effect on production of toxic shock syndrome toxin-1, 185
Contraceptive vaccines,
acceptability and effectiveness, 11
anti-hormone, 11
antigens in the male, 11
carriers, conjugation methods, adjuvants and vehicles, 11
methods for administration, 11
ovum antigens, 11
safety considerations, 11
use of recombinant DNA technology in development, 11
Contractility of uterine strips, effect of histamine and ZACE Montanoa tomentosa with Cimetidine and Diphenhydramine (guinea pig), 533
Contractility patterns, effect of zoapatle on uterine strips at different phases of estrous cycle (rat), 543
Contraction of uterine strips, effect of acetylcholine or ZACE Montanoa frutescens with atrophine (rat), 543
Copper T 200, effect on clinical chemistry and hormone levels, 321
Corticosterone level, effect of GnRH agonist (rat), 91
Cortisol level,
effect of copper T 200, 321
effect of levonorgestrel, 321
Cycle length,
effect of epostane (monkey), 479
normal menstrual cycles in Chinese women, 217
Danazol + testosterone enanthate, effect on biochemical composition of semen (monkey) 421
Deep vein thrombosis and oestrogen content in oral contraceptives, epidemiological analysis, 29
Dehydroepiandrosterone-sulphate level,
effect of ethinyl estradiol + desogestrel, 583
effect of ethinyl estradiol + levonorgestrel, 583
Delay of menses test, assessing endometrial effects of progestational agents, 557
Depo-medroxyprogesterone acetate,
effect on lipid and lipoprotein levels, 633
effects on carbohydrate and lipid metabolism, 51
return to ovulation following use, 361
Depo-medroxyprogesterone acetate + testosterone cypionate,
effect of serum lipids, 409
male contraceptive clinical trial, 409
Dimélys®, immediate postplacental insertion, 331

Diphenhydramine, effect on uterine strips (rat, guinea pig), 533
Discontinuation rates, failure of available contraceptive methods and family planning services in meeting demands of developing countries, 1
Duration of injections, effect of depo-medroxyprogesterone acetate on carbohydrate and lipid metabolism, 51
Early abortifacients, research and development needs, 1
Effectiveness, contraceptive vaccines, 11
Efficacy, use of morning-after ethinylestradiol + norgestrel, 275
Endocrine profile, use of ST-1435 subdermal capsules, 305
Endocrinological profile, normal menstrual cycles in Chinese women, 217
Endometrial cells, effect of β-momorcharin (mouse), 83
Endometrial effect,
  use of estradiol cypionate + medroxyprogesterone acetate, 453,
  use of estradiol valerate + norethisterone enanthate, 453
Endometrial histology, effect of vaginal administration of ethinyl oestradiol + norethisterone acetate, 571
Endometrium,
  effect of zoapatle (rat), 509
  level of ethynylestradiol, 43
β-Endorphin concentration, effect of GnRH agonist (rat), 91
Epididymal sperm, competition between seminal and exogenous proteinase inhibitors for binding sites (mouse), 177
Epileptic adolescents, interaction of anticonvulsants and oral contraceptives, 623
Epostane (Win 32729) [(4α ,5α ,17β)-4,5-epoxy-3,17-dihydroxy-4,17-dimethylandrost-2-ene-2-carbonitrile], effect on luteal phase progesterone level (monkey), 479
Estradiol + norethindrone, pharmacodynamics of contraceptive vaginal ring, 131
Estradiol + norethindrone vaginal ring, effect on ovarian function, bleeding control and lipoprotein patterns, 131
Estradiol cypionate + medroxyprogesterone acetate, pharmacokinetic and pharmacodynamic investigations, 453
Estradiol level,
  effect of copper T 200, 321
  effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
  effect of estradiol + norethindrone, 131
  effect of estradiol cypionate + medroxyprogesterone acetate, 453
  effect of estradiol valerate + norethisterone enanthate, 453
  effect of ethinyl estradiol + desogestrel, 583
  effect of ethinyl estradiol + levonorgestrel, 583
  effect of levonorgestrel, 71, 321
  effect of norethisterone, 71
  effect of ST-1435, 305
  normal menstrual cycles in Chinese women, 217
Estradiol valerate + norethisterone enanthate, pharmacokinetic and pharmacodynamic investigation, 453
Ethinylestradiol,
  effect on deep vein thrombosis, 29
  effect on pituitary response to GnRH, 295
Ethinylestradiol + cyproterone acetate, effect on pituitary response to GnRH, 295

Ethinylestradiol + desogestrel,
effect on pituitary response to GnRH, 295
effect on serum lipid and lipoprotein levels, 395
effects on sexual hormone levels, 583
Ethinylestradiol + levonorgestrel,
effect on serum lipid and lipopotein levels, 395
effects on sexual hormone levels, 583
Ethinylestradiol + lynestrenol,
effect on lipid and lipoprotein levels, 633
effect on pituitary response to GnRH, 295
Ethinylestradiol + norethisterone acetate,
effect on pituitary response to GnRH, 295
effects of vaginal administration, 571
Ethinylestradiol + norgestrel, morning-after pill, 275
Ethinylestradiol + d-norgestrel, effect on lipid and lipoprotein levels, 633
Ethynodiol diacetate,
norethisterone concentration in breast milk and infant and maternal plasma, 611
potency determined by delay of menses test, 557
potency determined by effect on lipids and lipoproteins, 557
potency determined by endometrial subnuclear vacuolization, 557
Ethynylestradiol,
level in endometrium 43
plasma level, 43
Ethynylestradiol + norgestrel, ethynylestradiol retained in blood and endometrium, 43
Evacuation of uterine conceptus, effect of chloroquine (rat), 173
Expulsion rate,
immediate post-abortion IUD insertion, 471, 603
immediate postplacental IUD insertion, 331
Female methods of contraception by year 2000, 1
FEMCEPT device, use in intrauterine applications of methyl cyanoacrylate for permanent sterilization, 243
Fertility, effect of gossypol (hamster), 141
Fertility rate, use of Malvaviscus conzattii flower extract (rat), 101
Fertility regulation, immunological methods, 11
Fever, immediate post-abortion IUD insertion, 603
First trimester pregnancy termination, preoperative cervical priming by intracervical application of sulprostone gel, 207
Follicular phase length, normal menstrual cycles in Chinese women, 217
Fructose level, effect of danazol + testosterone enanthate (monkey), 421
FSH (follicle stimulating hormone)
FSH level,
effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
effect of ethinyl estradiol + desogestrel, 583
effect of ethinyl estradiol + levonorgestrel, 583
effect of ST-1435, 305
normal menstrual cycles in Chinese women, 217
FSH release after GnRH double-stimulation, effect of various oral contraceptives, 295
Futurology, contraceptive, 1
Glucose level, effect of ethinyl oestradiol + norethisterone acetate, 571

Glucose tolerance test,
effect of depo-medroxyprogesterone acetate, 51
effect of ST-1435, 123
Glycerylphosphorylcholine level, effect of danazol + testosterone enanthate (monkey), 421
GnRH (gonadotrophin-releasing hormone)
GnRH agonist,
[(imBzl)-D-His6,Pro9-NEt]-GnRH, 91
D-(Nal)2^6-GnRH (naferelin acetate), 119
GnRH stimulation, pituitary response in comparative study of progestin-related effects, 295
Gossypol,
effect on fertility (hamster), 141
effect on macromolecular synthesis in testis (rat), 151
effect on testosterone production by Leydig cells (mouse), 165
(-)-Gossypol,
effect on testoterone release by Leydig cells (mouse), 159
male antifertiity agent (hamster), 141
separation procedure from racemate, 141
(+)-Gossypol, effect on testosterone release by Leydig cells (mouse), 159
(+) and (-) Gossypol, separation of enantiomers, 159
Group B-beta haemolytic streptococci, incidence of colonization in IUD users, 595
hCG (human chorionic gonadotropin)
Hematological parameters, effect of danazol + testosterone enanthate (monkey), 421
Heteroploidy-associated abnormalities, effect of IUCD on occurrence in spontaneous abortuses, 253
High density lipoproteins, factors which influence concentrations in blood, 367
Histamine, effect on uterine strips (rat, guinea pig), 533
17α-Hydroxyprogesterone level, effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
Ileostomy, effect on absorption of levonorgestrel, 195
[(imBzl)-D-His6, Pro9-NEt]-GnRH, effects on response to stress (rat), 91
Immediate post-abortion IUD insertion, 471, 603
Immediate postplacental IUD insertion, 331
Immunological methods of fertiilty regulation, workshop, 11
Implantation,
effect of indomethacin (rat), 445
effect of zoapatle (rat), 499
Indomethacin,
effect on implantation (rat), 445
effect on leukocytosis by intrauterine delivery (rat), 445
release rate from Silastic rods *in utero* (rat), 445
Infant plasma, norethisterone concentration during ethynodiol diacetate administration to breast-feeding mother, 611
Injectable contraceptive,
depo-medroxyprogesterone acetate, 51, 361, 633
estradiol cypionate + medroxyprogesterone acetate, 453
estradiol valerate + norethisterone enanthate, 453
norethisterone enanthate, 361
Insulin level,
effect of depo-medroxyprogesterone acetate, 51

effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
effect on ST-1435, 123
Interaction between SHBG and levonorgestrel released from vaginal ring, 431
Interaction of anticonvulsants and oral contraceptives in epileptic adolescents, 623
Intranasal contraceptive,
D-(Nal)2^6-GnRH, 119
D-Ser(TBU)^6-EA^{10}-LRH, 111
Intrauterine administration of ZACE Montanoa frutescens, effect on uterine morphology (rat), 509
Intrauterine administration of ZACE Montanoa tomentosa, effect on uterine morphology (rat), 509
Intrauterine administration of ZACE Montanoa tomentosa and Montanoa frutescens in same animal, comparative antiimplantation effect (rat), 499
Intrauterine application, methyl cyanoacrylate for permanent sterilization, 243
Intrauterine device (IUCD or IUD),
copper T 200, 321
Dimélys®, 331
effect on occurrence of heteroploidy-associated abnormalities in spontaneous abortuses, 253
immediate post-abortion insertion, 471
immediate postplacental insertion, 331
insertion immediately following induced abortion, 603
Lippes loop D, 331
MLCu250, 331, 471
MLCu375, 331, 471
Multiload 250, 603
Nova T, 603
Nova T-PP, 331
TCu200, 331
TCu220C, 331
Intrauterine instillation of ZACE Montanoa frutescens, effect on blastocyst implantation (rat), 499
Intrauterine instillation of ZACE Montanoa tomentosa, effect on blastocyst implantation (rat), 499
Intravaginal devices, amplification of toxic shock syndrome toxin-1, 185
IUCD or IUD (intrauterine device),
IUD users, incidence of group B-beta haemolytic streptococcal colonization, 595
Kauradienoic acid, relative potency in in vitro guinea pig uterine assay, 487
Kaurenoic acid, relative potency in in vitro guinea pig uterine assay, 487
Lactic dehydrogenase level, effect of danazol + testosterone enanthate (monkey), 421
Leaves of Montanoa frutescens, use of scanning electron microscope, 509
Leaves of Montanoa tomentosa, use of scanning electron microscope, 509
Leucine incorporation, effect of β-momorcharin (mouse), 83

Leukocytosis, effect of intrauterine delivery of indomethacin (rat), 445
Levonorgestrel,
absorption in women with ulcerative colitis, conventional ileostomy and continent ileostomy reservoir, 195
effect on clinical chemistry and hormone levels, 321
effect on levonorgestrel and progesterone levels with use of Silastic covered rods, 643
effect on ovarian function and quality of cervical mucus, 261
long-term clinical trial, 351
long-term experience, 231
pharmacodynamic effects, 431
potency determined by delay of menses test, 557
potency determined by effect on lipids and lipoproteins, 557
potency determined by endometrial subnuclear vacuolization, 557
released from vaginal ring and interaction with SHBG, 431
Levonorgestrel deposited directly in continent ileostomy reservoir, effect on absorption of levonorgestrel, 195
Levonorgestrel fused with cholesterol, clinical trial, 71
Levonorgestrel level,
effect of levonorgestrel pellet fused with cholesterol, 71
effect of subdermal implants releasing levonorgestrel, 261, 321
effect of vaginal ring releasing levonorgestrel, 431
use of levonorgestrel Silastic covered rods, 643
women with ulcerative colitis, conventional ileostomy and continent ileostomy reservoir, 195
Leydig cells,
effect of gossypol on testosterone production (mouse), 165
effect of (+) and (-) isomers of gossypol on testosterone release (mouse), 159
LH (luteinizing hormone)
LH level,
effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
effect of ethinyl estradiol + desogestrel, 583
effect of ethinyl estradiol + levonorgestrel, 583
effect of ST-1435, 305
normal menstrual cycles in Chinese women, 217
LH release after GnRH double-stimulation, effect of various oral contraceptives, 295
LH-stimulated release of testosterone,
effect of gossypol on Leydig cells (mouse), 165
effect of (+) and (-) gossypol on Leydig cells (mouse), 159
Lipid concentrations,
effect of long-term hormonal contraception, 633
effect of oral contraceptives, 367
in women aged 20-49 years, 367
Lipid metabolism,
effect of depo-medroxyprogesterone acetate, 51
effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
effect of ethinylestradiol + desogestrel, 395
effect of ethinylestradiol + levonorgestrel, 395
effect of oral contraceptive use and development of cardiovascular

disease, 367
review, 367
Lipids and cardiovascular disease, 367
Lipids and lipoproteins, effects of various progestins, 557
Lipoprotein characteristics, 367
Lipoprotein metabolism, effect of ST-1435, 123
Lipoprotein level,
effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
effect of estradiol + norethindrone, 131
effect of ethinylestradiol + desogestrel, 395
effect of ethinylestradiol + levonorgestrel, 395
effect of ethinyl oestradiol + norethisterone acetate, 571
effect of long-term hormonal contraception, 633
effect of oral contraceptives, 367
effect of ST-1435, 123
Lippes loop D, immediate postplacental insertion, 331
Liver function tests, effect of ST-1435, 305
Local reaction, norethisterone or levonorgestrel pellet fused with cholesterol, 71
Long-term clinical trial, Silastic covered rods containing levonorgestrel, 351
Long-term experience, Norplant® contraceptive implants, 231
Long-term use of hormonal contraception, effect on lipid and lipoprotein levels, 633
LRH (luteinizing hormone-releasing hormone)
LRH agonist, D-Ser(TBU)^{6}-EA^{10}-LRH (buserelin), 111
Luminal cell counts, effect of indomethacin (rat), 445
Luteal phase length, normal menstrual cycles in Chinese women, 217
Luteal phase progesterone level, effect of epostane (monkey), 479
Lynestrenol, effect on lipid and lipoprotein levels, 633
Macromolecular synthesis, effect of gossypol in testis (rat), 151
Magnesium level, effect of danazol + testosterone enanthate (monkey), 421
Male antifertility agent,
gossypol (mouse), 159, 165
(-)-gossypol (hamster), 141
Male contraceptive,
danazol + testosterone enanthate (monkey), 421
depo-medroxyprogesterone acetate + testosterone cypionate, 409
medroxyprogesterone acetate + methyltestosterone, 65
Male contraceptive agent, gossypol (rat), 151
Male fertility, effect of Malvaviscus conzattii flower extract (rat), 101
Male methods of contraception by year 2000, 1
Malvaviscus conzattii flower extract, effect on male fertility (rat), 101
Mating rate, use of Malvaviscus conzattii flower extract (rat), 101
Mechanism of action, morning-after ehinylestradiol + norgestrel, 275
Medroxyprogesterone acetate + methyltestosterone, effect on sexual functioning in male contraceptive trial, 65
Medroxyprogesterone acetate level, effect of injectable estradiol cypionate + medroxyprogesterone acetate, 453
Menstrual cycle day, use of morning-after ethinylestradiol + norgestrel and expected vs observed number of pregnancies, 275

Menstrual cycles, endocrinological profile in Chinese women, 217
Menstrual flow duration, effect of morning-after ethinylestradiol + norgestrel, 275
Menstrual pattern, effect of morning-after ethinylestradiol + norgestrel, 275
Menstrual problems, effect of levonorgestrel, 231
Menstruation, return following use of long-acting injectable contraceptives, 361
Mestranol, effect on deep vein thrombosis, 29
Mestranol + norethisterone, effect on lipid and lipoprotein levels, 633
Metabolic parameters,
  effect of levonorgestrel, 71
  effect of norethisterone, 71
Methyl cyanoacrylate, intrauterine applications for permanent sterilization, 243
4-Methylumbelliferyl-p-guanidinobenzoate, effectiveness as competitor with seminal inhibitor for binding to epididymal sperm (mouse), 177
MLCu250,
  immediate post-abortion insertion, 471
  immediate postplacental insertion, 331
MLCu375,
  immediate post-abortion insertion, 471
  immediate postplacental insertion, 331
β-Momorcharin,
  effect on biosynthetic activity of cultured endometrial cells (mouse), 83
  effect on endometrial cells (mouse), 83
Monoclonal antibody techniques, identifying sperm-specific antigens, 11
Montanol, relative potency in in vitro guinea pig uterine assay, 487
Morning-after pill, ethinylestradiol + norgestrel, 275
Multiload 250, immediate post-abortion insertion, 603
Na-benzol-L-arginine ethyl ester, effectiveness as competitor with seminal inhibitor for binding to epididymal sperm (mouse), 177
D-(Nal)2^6-GnRH, effect on ovulation, 119
Natural family planning methods, research needs, 1
Natural proteinase inhibitors, effectiveness as competitor with seminal inhibitor for binding to epididymal sperm (mouse), 177
p-Nitrophenyl-p-guanidinobenzoate, effectiveness as competitor with seminal inhibitor for binding to epididymal sperm (mouse), 177
Noradrenaline, effect on uterine strips (rat), 543
Norethindrone,
  potency determined by delay of menses test, 557
  potency determined by effect on lipids and lipoproteins, 557
  potency determined by endometrial subnuclear vacuolization, 557
Norethindrone acetate,
  potency determined by delay of menses test, 557
  potency determined by effect on lipids and lipoproteins, 557
  potency determined by endometrial subnuclear vacuolization, 557
Norethindrone level, effect of vaginal ring releasing estradiol + norethindrone, 131
Norethisterone enanthate, return to ovulation following use, 361
Norethisterone fused with cholesterol, clinical trial, 71

Norethisterone level,
after administration of ethynodiol diacetate, 611
effect of injectable estradiol valerate + norethisterone enanthate, 453
effect of norethisterone pellet fused with cholestrol, 71
in breast milk after administraiton of ethynodiol diacetate, 611
in infant plasma after administration of ethynodiol diacetate to breast-feeding mother, 611
Norgestrel,
potency determined by delay of menses test, 557
potency determined by effect on lipids and lipoproteins, 557
potency determined by endometrial subnuclear vacuolizaiton, 557
Normal menstrual cycles, endocrinological profile in Chinese women, 217
Norplant® subdermal implants,
effect on ovarian function and quality of cervical mucus, 261
long-term experience, 231
Nova T, immediate post-abortion insertion, 603
Nova T-PP, immediate postplacental insertion, 331
Oestradiol level,
effect of GnRH agonist, 119
effect of LRH agonist, 111
Oestrogen content in oral contraceptives and deep vein thrombosis, epidemiological analysis, 29
Once-a-month agents, research and development needs, 1
Oral contraceptive,
ethinylestradiol + cyproterone acetate, 295
ethinylestradiol + desogestrel, 295, 395, 583
ethinylestradiol + levonorgestrel, 395, 583
ethinylestradiol + lynestrenol, 295, 633
ethinylestradiol + norethisterone acetate, 295
ethinylestradiol + d-norgestrel, 633
ethinyl oestradiol + l-norgestrel, 195
ethynodiol diacetate, 611
ethynylestradiol + norgestrel, 43
lynestrenol, 633
mestranol + norethisterone, 633
Oral contraceptives,
effect on serum lipid levels and development of cardiovascular disease, 367
oestrogen content and deep vein thrombosis, 29
relative potency of progestins, 557
Oral contraceptives and anticonvulsants, interaction in epileptic adolescents, 623
Oral contraceptives and cardiovascular disease 367
Ovarian function,
effect of estradiol + norethindrone, 131
effect of levonorgestrel released from vaginal ring, 431
effect of Norplant® contraceptive implants, 261
effect of ST-1435 subdermal capsules, 305
Ovulation,
effect of levonorgestrel, 261
effect of levonorgestrel Silastic covered rods, 643
effect of D-(Nal)^{2}^{6}-GnRH, 119

effect of D-Ser(TBU)^{6}-EA^{10}-LRH, 111
return following use of long-acting injectable contraceptives, 361
Pain, immediate post-abortion IUD insertion, 603
Pelvic inflammatory disease, immediate post-abortion IUD insertion, 603
Peptide contraception, intranasal LRH agonist therapy, 111
Perception of consequences, contraceptives futurology, 1
Performance, immediate postplacental IUD insertion, 331
Performance of copper IUDs,
according to characteristics of recipient, 331
according to model, 331
according to operator's skill, 331
Pharmacodynamic effects, levonorgestrel released from vaginal ring, 431
Pharmacodynamics, contraceptive vaginal ring releasing estradiol + norethindrone, 131
Pharmacokinetics and pharmacodynamics,
estradiol cypionate + medroxyprogesterone acetate, 453
estradiol valerate + norethisterone enanthate, 453
Phospholipids level,
effect of ethinylestradiol + desogestrel, 395
effect of ethinylestradiol + levonorgestrel, 395
Pituitary function, effect of SI-1435 subdermal capsules, 305
Pituitary response to GnRH and oral contraceptives, comparative study of progestin-related effects, 295
Pluronic F 127 gelatinising agent + sulprostone, intracervical application for preoperative cervical priming, 207
Population size, projected, 1
Post-coital agents, research and development needs, 1
Postcoital interception, ethinylestradiol + norgestrel, 275
Post-coital test,
effect of levonorgestrel, 71, 261
effect of norethisterone, 71
Potassium, effect on uterine strips (rat), 543
Potency of progestins used in oral contraceptives, 557
Pregnancy, use of SI-1435, 305
Pregnancy rate,
immediate post-abortion IUD insertion, 471
immediate postplacental IUD insertion, 331
use of intrauterine applications of methyl cyanoacrylate for permanent sterilization, 243
use of levonorgestrel, 231
use of levonorgestrel Silastic covered rods, 351
use of morning-after ethinylestradiol + norgestrel, 275
Probability of conception after coitus in absence of contraception by menstrual cycle day, 275
Proctocolectomy with ileostomy, effect on absorption of levonorgestrel, 195
Progesterone level,
effect during luteal phase by epostane (monkey), 479
effect during luteal phase by hCG + epostane (monkey), 479
effect of estradiol + norethindrone, 131
effect of estradiol cypionate + medroxyprogesterone acetate, 453
effect of estradiol valerate + norethisteorne enanthate, 453
effect of ethinyl estradiol + desogestrel, 583
effect of ethinyl estradiol + levonorgestrel, 583
effect of ethinyl oestradiol + norethisterone acetate, 571

effect of GnRH agonist, 119
effect of levonorgestrel, 71, 261, 643
effect of LRH agonist, 111
effect of norethisterone, 71
effect of SI-1435, 305
normal menstrual cycles in Chinese women, 217
Progestin potency, oral contraceptives availabale in the U.S. which contain 50 μg or less of estrogen, 557
Progestin-related effects, comparative study on oral contraceptives and pituitary response to GnRH, 295
Progestins,
effect on lipids and lipoproteins, 557
relative potency, 557
Projected population size, 1
Prolactin level,
effect of ethinyl estradiol + desogestrel, 583
effect of ethinyl estradiol + levonorgestrel, 583
normal menstrual cycles in Chinese women, 217
Propranolol, effect on uterine strips (rat), 543
Prostaglandin analog, sulprostone, 207
Protein level, effect of ethinyl oestradiol + norethisterone acetate, 571
Protein proteinase inhibitors, effectiveness as competitor with seminal inhibitor for binding to epididymal sperm (mouse), 177
Proteinase inhibitors, competition between seminal and exogenous inhibitors for sites on epididymal sperm (mouse), 177
Rectum, incidence of group B-Beta haemolytic streptococcal colonization, 595
Red cells, effect of zoapatle, 523
Relative potency, zoapatle aqueous crude extract and compounds isolated from same plant, 487
Relative potency of progestins in oral contraceptives, 557
Relaxation of uterine strips,
effect of histamine and ZACE Montanoa tomentosa with Cimetidine and Diphenhydramine (rat), 533
effect of noradrenaline or ZACE Montanoa tomentosa with propranolol (rat), 543
Release rate,
indomethacin from Silastic rods in utero (rat), 445
levonorgestrel from Silastic covered rods, 351
Removals, use of SI-1435, 305
Removal rate,
immediate post-abortion IUD insertion, 471, 603
immediate postplacental IUD insertion, 331
Response to stress, effect on GnRH agonist (rat), 91
Return to menstruation,
following use of depo-medroxyprogesterone acetate, 361
following use of norethisterone enanthate, 361
Return to ovulation,
following use of depo-medroxyprogesterone acetate, 361
following use of norethisterone enanthate, 361
Safety considerations, development of contraceptive vaccines, 11
Seizure control, effect of interaction of anticonvulsants and oral contraceptives in epileptic adolescents, 623

Semen, effect of danazol + testosterone enanthate on biochemical composition (monkey), 421
Semen volume, effect of danazol + testosterone enanthate (monkey), 421
Seminal inhibitor, competition with exogenous proteinase inhibitors for binding to epididymal sperm (mouse), 177
Separation,
(-)-gossypol from racemate, 141
(+) and (-) isomers of gossypol, 159
D-Ser(TBU)^{6}-EA^{10}-LRH, effect on ovulation, 111
Sex hormone binding globulin (SHBG), interaction with levonorgestrel released from vaginal ring, 431
Sexual behavior, effect of medroxyprogesterone acetate + methyltestosterone in male contraceptive trial, 65
Sexual perception, effect of medroxyprogesterone acetate + methyltestosterone in male contraceptive trial, 65
SHBG (sex hormone binding globulin)
SHBG level,
effect of depo-medroxyprogeterone acetate + testosterone cypionate, 409
effect of levonorgestel, 431
Side effects,
use of morning-after ethinylestradiol + norgestrel, 275
use of ST-1435 subdermal capsules, 305
use of sulprostone gel, 207
vaginal administration of ethinyl oestradiol + norethisterone acetate, 571
Sperm antigen vaccines, 11
Sperm count,
effect of danazol + testosterone enanthate (monkey), 421
effect of Malvaviscus conzattii flower extract (rat), 101
Sperm motility,
effect of danazol + testosterone enanthate (monkey), 421
effect of Malvaviscus conzattii flower extract (rat), 101
effect of zoapatle, 523
Sperm viability, effect of zoapatle, 523
Sperm-specific antigens, use of monoclonal antibodies, 11
Spontaneous abortions, with/without IUCD in situ, 253
Spontaneous abortuses, effect of IUCD on occurrence of heteroploidy-associated abnormalities, 253
ST-1435 (16-methylene-17α-acetoxy-19-nor-4-pregnen-3,20-dione),
effect on lipoprotein and carbohydrate metabolism, 123
side effects, endocrine profiles and liver function, 305
ST-1435 level, use of subdermal implants releasing ST-1435, 305
Sterilization, use of methyl cyanoacrylate intrauterine applications, 243
Stress, effect on response when treated with GnRH agonist (rat), 91
Subdermal implant contraceptive,
levonorgestrel, 231, 261, 321, 351, 643
levonorgestrel fused with cholesterol, 71
norethisterone fused with cholesterol, 71
ST-1425, 123, 305
Subnuclear vacuolizaiton, assessing endometrial effects of progestational agents, 557
Sulprostone + Pluronic F 127, intracervical application for preoperative cervical priming, 207

Sulprostone gel, use for preoperative cervical priming, 207
Synthetic proteinase inhibitors, effectiveness as competitor with seminal inhibitor for binding to epididymal sperm (mouse), 177
Tampons, effect on production of toxic shock syndrome toxin-1, 185
TCu200, immediate postplacental insertion, 331
TCU220C, immediate postplacental insertion, 331
Termination rate,
  immediate post-abortion IUD insertion, 471
  use of levonorgestrel, 231
  use of levonorgestrel Silastic covered rods, 351
Testis,
  effect of gossypol on macromolecular synthesis (rat), 151
  effect on Malvaviscus conzattii flower extract (rat), 101
Testosterone level,
  effect of copper T 200, 321
  effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
  effect of ethinyl estradiol + desogestrel, 583
  effect of ethinyl estradiol + levonorgestrel, 583
  effect of levonorgestrel, 321
Testosterone production, effect of gossypol on Leydig cells (mouse), 165
Testosterone release, effect of (+) and (-) isomers of gossypol on Leydig cells (mouse), 159
Thymidine incorporation,
  effect of gossypol (rat), 151
  effect of β-momorcharin (mouse), 83
Thyroid stimulating hormone level,
  effect of copper T 200, 321
  effect of levonorgestrel, 321
Thyroxine level,
  effect of copper T 200, 321
  effect of levonorgestrel, 321
Tissue weights, effect of GnRH agonist (rat), 91
Tomexanthin, structural formula, 487
Tonometric study, effect of sulprostone gel, 207
Toxic shock syndrome toxn-1, amplification by intravaginal devices, 185
Triglycerides level,
  effect of depo-medroxyprogesterone acetate, 51
  effect of depo-medroxyprogesterone acetate + testosterone cypionate, 409
  effect of estradiol + norethindrone, 131
  effect of ethinylestradiol + desogestrel, 395
  effect of ethinylestradiol + levonorgestrel, 395
  effect of long-term hormonal contraception, 633
  effect of oral contraceptives, 367
  effect of ST-1435, 123
Triiodothyronine level,
  effect of copper T 200, 321
  effect of levonorgestrel, 321
Tubal closure rate, use of methyl cyanoacrylate, 243
Ulcerative colitis, effect on absorption of levonorgestrel, 195
United Nations World Population Conference, Mexico City, 1984, recommendation no. 69, 1

Unwanted births, failure of available contraceptive methods and family planning services in developing counties, 1
Urethra, incidence of group B-beta haemolytic streptococcal colonization, 595
Uridine incorporation,
  effect of gossypol (rat), 151
  effect of β-momorcharin (mouse), 83
Uterine conceptus, effect of chloroquine (rat), 173
Uterine morphology,
  effect of ZACE Montanoa frutescens (rat), 509
  effect of ZACE Montanoa tomentosa (rat), 509
Uterine strips,
  effect of zoapatle (rat), 543
  effect of zoapatle (rat, guinea pig), 533
Uterine weight, effect of β-momorcharin (mouse), 83
Vaccine development, carriers, conjugation methods, adjuvants and vehicles, 11
Vaccines, use in fertility regulation, 11
Vagina, incidence of group B-beta haemolytic streptococcal colonization, 595
Vaginal administration, oral contraceptive containing ethinyl oestradiol + norethisterone acetate, 571
Vaginal discharge, incidence of group B-beta haemolytic streptococcal colonization, 595
Vaginal ring contraceptive,
  estradiol + norethindrone, 131
  levonorgestrel, 431
Workshop, research and development of immunological methods of fertility regulation, 11
ZACE (zoapatle aqueous crude extract)
ZACE Montanoa frutescens,
  effect on implantation (rat), 499
  effect on motility of sperm, 523
  effect on red cells, 523
  effect on uterine strips (rat), 543
  effect on viability of sperm, 523
  relative potency in in vitro guinea pig uterine assay, 487
ZACE Montanoa tomentosa,
  effect on implantation (rat), 499
  effect on red cells, 523
  effect on uterine strips (rat), 543
  effect on uterine strips (rat, guinea pig), 533
  effect on viability of sperm, 523
  relative potency in in vitro guinea pig uterine assay, 487
Zoapatanol, relative potency in in vitro guinea pig uterine assay, 487
Zoapatanolides A, B, C and D, structural formulae 287
Zoapatle,
  effect in endometrium (rat), 509
  effect on implantation (rat), 499
  effect on red cells, 523
  effect on sperm, 523
  effect on uterine strips (rat), 543
  effect on uterine strips (rat, guinea pig), 533

review of new publications, 487
revisited, 487
Zona pellucida antigens,
efficacy of immunization, 11
isolation and characterization, 11
potential problems and drawbacks, 11
quantitation of immune response, 11